Press Releases

Date Title  
Toggle Summary Natera Reports Fourth Quarter and Year 2019 Financial Results
SAN CARLOS, Calif. , Feb. 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and the year ended December 31, 2019 and provided an update on recent
Toggle Summary Natera Announces Fourth Quarter and Fiscal 2019 Earnings Conference Call
SAN CARLOS, Calif. , Feb. 19, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019 , after the market close on February 26, 2020 .
Toggle Summary Natera Files False Advertising Counterclaim Against CareDx
CareDx's advertising obfuscates AlloSure's poor performance SAN CARLOS, Calif. , Feb. 18, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it has filed suit against CareDx for false advertising in the U.S.
Toggle Summary Natera Files Suit Against ArcherDX for Patent Infringement
SAN CARLOS, Calif. , Jan. 27, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) a global leader in cell-free DNA testing, filed suit today against ArcherDX for infringement of Natera's U.S. Patent No. 10,538,814 (the "'814 patent"). The complaint was filed in the U.S. District Court of Delaware .
Toggle Summary National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera™ MRD Testing in Stage II-III Colorectal Cancer
Pivotal Study of 1500 Patients Could Lead to Change in Practice Guidelines SAN CARLOS, Calif. , Jan. 15, 2020 /PRNewswire/ -- Today Natera, Inc. (NASDAQ: NTRA) announced an agreement with the National Cancer Center (NCC) Japan to launch the CIRCULATE-IDEA trial in Japan , a prospective,
Toggle Summary Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx
Adds to Natera's Extensive Suite of More Than 200 Issued and Pending Patents SAN CARLOS, Calif. , Jan. 13, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today filed suit against CareDx for infringing its U.S.
Toggle Summary Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera™ Patients with Stage II-III Colorectal Cancer
Study to quantify changes in post-surgical treatment and impact of early relapse detection using Signatera test SAN CARLOS, Calif. , Jan. 9, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a nationwide multi-center registry study called
Toggle Summary Natera To Webcast Live Presentation at the 38th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif. , Jan. 8, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday,
Toggle Summary Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents
Exceeds 2019 goal of $40-$50 million in cumulative contracts with pharmaceutical companies and extends leadership in ctDNA MRD SAN CARLOS, Calif. , Jan. 6, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it has exceeded its 2019 goal of
Toggle Summary Natera Receives Final Medicare Coverage for Prospera™ Organ Transplant Rejection Assessment Test
Coverage Expanded Beyond Initial Draft Local Coverage Decision SAN CARLOS, Calif. , Dec. 19, 2019 /PRNewswire/ -- Natera, Inc.   (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Medicare has finalized its local coverage determination (LCD) to provide insurance coverage

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.